CURRICULUM VITAE

Full Name:	Nikolov	Boris	S
	Last Name	First Name	Middle Initial

Professional Mailing Address: (Include institution name.)

IMIC Inc
18320 Franjo Rd (aka SW 97 Ave)
Palmetto bay, FL 33157

Telephone: 305-338-0568/ fax 305-252-2199, email: boris@aktamedika.com

Academic Qualifications (most current date first)

Degree/Certification	Date (YYYY)	Institution, Country
CCRC	2011	ACRP
GCP Course	2016	CITI, multiple courses
Medical Doctor	1994	Higher Medical Institute – Sofia, Bulgaria/

Current and Previous Relevant Positions Including Academic Appointments (most current date first):

Start and End Dates	Title	Institution or Company, State/Province/Country
2012-current	Research coordinator, Sub-I, Research Manager	IMIC Inc.
2009-2012	Clinical research Dept Manager, Sub-I	Diagnostic Consultative Center "Akta Medika" EOOD, Sevlievo, Bulgaria/
2006-2009	CRC, Research and development Manager	HealthRight Medical clinic, Miami, USA
2005-2006	Intern Internal medicine	University of Miami, Jackson Memorial Hospital, Miami USA
2000-2005	Manager Emergency Services	Doctor Correa International, Dominican Republic
1994-2000	Pediatrician, Manager Medical Services	IKAR Private practice and school, Sofia Bulgaria

Brief Summary of Relevant Clinical Research Experience in the last 10 years:

Participation in 35 Clinical studies as SI and 57 studies as clinical coordinator in trials phase 1,2, 3 and 4 in cardiology – unstable angina, hypercholesterolemia, stable angina, hypertension; pulmonology – COPD and Asthma; endocrinology-diabetes type 2 multiple compounds; rheumatology – multiple compounds in osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis; urology – stress urinary incontinence, neurology-epilepsy, fibromyalgia, back pain, migraine; psychiatry – depression, bipolar disorder, ADHD, schizophrenia, mild, moderate and severe Alzheimer's disease, AD with behavioral changes and gastroenterology – GERD: OIC, CIC, cirrhosis, IBD.

Psychometric Scale administration proficiency since 2012: CDR, ADAS-Cog, ADCS-CGIC, ADCS-ADL, CGIS, CGII, CGI, CMAI, CSDD, GMHR, mADCS-CGIC, MMSE, NPI, S-STS, TUG, ZBI, ESS, ADL, C-SSRS, RBANS, LCFT, DSCT, ED-5D, RUD-Lite

IWRS experience since 2009: Clinphone, iMedidata, eCaselink, iwrsppdi, Phaseforward, Bracketglobal, McDougall Scientific , PrGrand i-360, Bioclinica, Cenduit,

EDC experience since 2009: Inform, OC-RDC, iMedidata, Medrio, Datalabs, Eclinical, Express Bioclinica, Viedoc, Perceptive MyTrials,

ePRO experience since 2009: ERT, CRF Trialmanager, Biomedical Systems, PhT,

Psychometric ratings online experience since 2012: Virgil Portal, Bracket, Medavante, Cogstate

Detailed description of participation in trials in the past 5 years:

2016 - A Phase 3 Multi-Center, Randomized, Double- Blinded, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy, Tolerability and Safety of Once Daily SB204 and Vehicle Gel in the Treatment of Acne Vulgaris as SI

2016 - IDN-6556-14: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension as SI

2016 - A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF GED-0507-34-LEVO (GED0507) FOR TREATMENT OF SUBJECTS WITH ACTIVE ULCERATIVE COLITIS, GED0507-UC-001 as SI

2016 - A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of AVP-786 (deuterated [d6]-dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer's type as SI

2016 - A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks Sol-Gel Protocol Number: SGT-65-02 as SI

2016 - A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti-Tumor Necrosis Factor-Alpha Therapy as SI

2016 - GA28951: AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE III STUDIES as SI

2015 - 000175 -A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 2 g Extended Release Granules (Sachet) for Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis as SI

2015 - M13-740 -A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects with Moderately to Severely Active Crohn's Disease who have Inadequately Responded to or are Intolerant to Anti-TNF Therapy as SI

2015 - BLI400-303: An Open Label Study of Chronic Use of BLI400 Laxative in Constipated Adults as CTC

2015 - 000174 - A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 4 g Extended Release Granules (Sachet) for the Induction of Clinical and Endoscopic Remission in Active, Mild to Moderate Ulcerative Colitis as SI

2015 - SP333101-04, A Phase 1b, Exploratory, Double Blind, Placebo-Controlled Four-Week Study of Rectally Administered SP-333 for the Treatment of Patients with Mildly to Moderately Active Left-Sided Ulcerative Colitis as SI

2015 - PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY (MAINTENANCE OF REMISSION) AND SAFETY OF ETROLIZUMAB COMPARED WITH PLACEBO IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO ARE NAIVE TO TNF INHIBITORS as SI

2015 - GT-026: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients with NASH Cirrhosis. The NASH-CX Trial as SI

2015- GA29144 - A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE as SI

2015 - A Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects with Evidence of Early Alzheimer's Disease as SI

2015 - A Multicenter, Double-blind, Placebo- and Active-Controlled Parallel-Group Evaluation of the Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder as SI

2015- An Open-label Long-term Safety Study of Vilazodone in Pediatric Patients with Major Depressive Disorder as SI

2016- Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Adjunctive Therapy in Subjects with Signs and Symptoms of Osteoarthritis of the Hip or Knee as SI

2016 - A randomized, double-blind, placebo controlled study to evaluate the safety, tolerability and clinical effect of oral danirixin (GSK1325756) in the treatment of healthy adults with acute, uncomplicated influenza (201682) as SI

2015- A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-ranging Study of Vapendavir in Moderate to Severe Asthmatic Adults with Symptomatic Human Rhinovirus Infection as SI

2015- A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Outpatients with Early Alzheimer's Disease as Sub-I

2015- phase 3 - A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β_2-Agonist (STRATOS 2) as SI

2015- phase 3 - *A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults as SC*

2015 – Phase 3 A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 in Subjects with Pain Associated with Fibromyalgia. Protocol Code: DS5565-A-E311 as CRC

2015- phase 3 - A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β_2-Agonist (STRATOS 2) as SC

2014 – Phase 1 OTT329/305: CLINICAL ENDPOINT STUDY OF SALMETEROL XINAFOATE/FLUTICASONE PROPIONATE COMBINATION FOR COMPARISON OF A TEST AND REFERENCE PRODUCT IN PATIENTS WITH ASTHMA AS CRC

2014- An Efficacy and Safety Study of Sustained-release Paracetamol in Subjects with Osteoarthritis as SI

2014 - a phase 3 double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy, long-term safety and tolerability of pf-04950615 in subjects with primary hyperlipidemia or mixed dyslipidemia at risk of cardiovascular events as CRC

2014 – PHASE 3 A LONG-TERM OUTCOMES STUDY TO ASSESS STATIN RESIDUAL RISK REDUCTION WITH EPANOVA IN HIGH CARDIOVASCULAR RISK PATIENTS WITH HYPERTRIGLYCERIDEMIA AS CRC

2014 – PHASE 2 A Randomized, Double Blind, Double Dummy, Placebo Controlled, Parallel Group, 12 Week Clinical Study to Assess the Efficacy and Safety of 80 or 160 mcg/Day of Beclomethasone Dipropionate Delivered via Breath Actuated Inhaler (BAI) or Metered Dose Inhaler (MDI) in Pediatric Patients 5 Through 11 Years of Age with Persistent Asthma as CRC

2014 – Phase 1, A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared with Advair Diskus® 100/50 in Subjects with Asthma, FLSA-P100/50-PVCL as CRC

2014 – Phase 2 New Chapter protocol #NEWC2600: Polyherbal capsule formulation for joint health: a multicenter, 2-arm, randomized, double-blind, placebo-controlled study as CTC

2014- Phase 3 A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission with Endoscopic Response at 16 Weeks followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects with Active Moderate Crohn's Disease as CRC

2014 - A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of benralizumab (MEDI-563) added to High Dose Inhaled Corticosteroid plus Long-acting β2 Agonist in Patients with Uncontrolled Asthma (CALIMA)
As CRC

2014 - A Randomised, Double-blind, Double Dummy, Chronic Dosing (56 week) Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of 3 Doses of Benralizumab (MEDI-563) in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (TERRANOVA) as CRC

2014 - A National, Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients with Chronic Idiopathic Constipation as CRC

2014 - A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients with Type 2 Diabetes Mellitus as CTC

2014 - A randomized, double-blind, placebo-controlled, dose-ranging, multicenter study to assess the efficacy and safety of rifaximin soluble solid dispersion (SSD) tablets for the prevention of complications in subjects with early decompensated liver cirrhosis as CTC

2014 A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Naldemedine in the Treatment of Opioid-induced Constipation in Subjects with Non-malignant Chronic Pain Receiving Opioid Therapy as CTC

2013- A randomized double-blind placebo controlled parallel group study of the efficacy and safety of pregabalin (bid) in subjects with post-traumatic peripheral neuropathic pain as CTC

2013- MKC-TI-134. A Phase 3, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects with Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12-month Treatment Period with a 2-month Follow-up as CTC

2013- A Randomized, 4-Week, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC) in Patients with Non-malignant Chronic Pain Receiving Opioid Therapy as CTC

2013- Dey **Protocol 191-091**: Phase II - A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Nebulized Fluticasone Propionate (FP) Dose Response in Adult Subjects with Partly Controlled and Uncontrolled Asthma as CTC.

2013 - Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients with Moderate to Very Severe COPD (ASCENT COPD) as CRC

2013 - DECLARE-TIMI 58 study (Dapagliflozin Effect on CardiovascuLAR Events) as CTC

2013 - Phase II - A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study to Replicate Efficacy of Nebulized Fluticasone Propionate (FP) in Adult Subjects with Partly Controlled and Uncontrolled Asthma as CTC

2013 – Phase 4 - A 26 week, randomized, double-blind, parallel-group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma-related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2-agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma as CTC

2013 – Phase 3 - ONU3705 A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-induced Constipation (Compared to Oxycodone Controlled-release Tablets (OXY)) in Opioid-experienced Subjects with Controlled Moderate to Severe Chronic Low Back Pain and a History of Opioid-induced Constipation who Require Around-the clock Opioid Therapy as CTC

2013 - A Placebo-Controlled, Double-Blind, Parallel, Randomized, Clinical Dose-Confirming Study of Pulsed, Inhaled Nitric Oxide (iNO) in Subjects with World Health Organization (WHO) Group 3Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD) on Long-Term Oxygen Therapy (LTOT) as CTC

2013-Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT) as CTC

2012-MB102073: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with inadequately controlled hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) as CTC

2012-MB102077: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with inadequately controlled hypertension treated with an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) and an additional Antihypertensive medication as CTC

2011-Once-A-Day Pregabalin For Partial Seizures, phase 3 as Sub-I

2012-Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis, phase 2 as Sub-I

2012-A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis as Sub-I

2012- Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic

Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide as Sub-I

2011- Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination as Sub-I

2011- Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease as Sub-I

2012- New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day (BAI) as Sub-I

2012- Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA) (OSKIRA -4) as Sub-I

2012- Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding. (OSKIRA - 1) as CTC

2012- Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA) (OSKIRA-X) as CTC

2012- D5132C000001, Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS) as CTC

2012- Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus as CTC

2012- Tecos: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment withSitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control, as CTC

2012- phase 3 - Trial of CF101 to Treat Patients With Dry Eye Disease as CTC

2012- Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD (CARSAF) as CTC

2011- M/40464/30 A phase III double-blind, randomized, parallel group, multicentre study, to investigate the efficacy and safety of an aclidinium bromide/ formoterol fumarate fixed dose combination compared with each individual component and placebo when administered to patients with stable chronic obstructive pulmonary disease (COPD) as CTC

2012- phase 3, Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients as CTC

2011-phase 3 - Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients (Neptune), as CTC

2011- A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1) as CTC

2012-phase 3 - An Open Label Study for Patients With Rheumatoid Arthritis as CTC

2012- phase 3 - A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate (FLEX M) as CTC

2012-phase 3 - A Rheumatoid Arthritis Study in Patients (FLEX O) as CTC

2011- phase 3 -The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial) as Sub-I

2012-phase 2 - A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy as Sub-I

2011-phase 2 - A Study of CH-4051 in Patients With Rheumatoid Arthritis (RA) (MOTION) as Sub-I

2012-phase 2 - Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate as CTC

2012-phase 2 - Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis (Oskira ABPM) as CTC

2012-phase 2 - A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis as Sub-I

2012- Innovacell Study IC-01-01-05-004, A multicenter, randomized, parallel-group, placebo-controlled study to assess the efficacy and safety of skeletal muscle-derived cell implantation in female patients with stress urinary incontinence as CTC

2012- Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome (EXAMINE)As CTC

2011- Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease as CTC

2011-phase 2 - Initial Treatment for Acute Bacterial Skin Infections (ABSSSI) Caused by Staphylococcus Aureus as CTC

2012- phase 3 - A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease As Sub-I

2011-phase 3- A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy as Sub-I

2012- phase 2 - Long Term Safety Trial of z102 and Prednisone in Patients With Moderate to Severe Rheumatoid Arthritis as CTC

2011 – Phase 3 - Diltiazem Hydrochloride Cream for Anal Fissure, as Sub-I

2011-phase 2 - A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis (Synergy) as CTC

Signature:	**Signature Date:**
	30 OCT 16